HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIB	ER	PATIENT:		
Name:					
Ward:	:		NHI:		
Abiraterone acetate					
Re-a	iaiupe P	ment tes (required after 6 months tick boxes where appropriate) ribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has endorsed by the Health NZ Hospital.		
and	and ($\overline{}$	Patient has prostate cancer Patient has metastases		
	and (and	O	Patient's disease is castration resistant		
		or	Patient is symptomatic and Patient has disease progression (rising serum PSA) after second line anti-androgen therapy Patient has ECOG performance score of 0-1 and Patient has not had prior treatment with taxane chemotherapy Patient's disease has progressed following prior chemotherapy containing a taxane Patient has ECOG performance score of 0-2 and Patient has not had prior treatment with abiraterone		
CONTINUATION Re-assessment required after 6 months Prerequisites (tick boxes where appropriate) O Prescribed by, or recommended by a medical oncologist, radiation oncologist or urologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.					
	and and and	C	Significant decrease in serum PSA from baseline No evidence of clinical disease progression No initiation of taxane chemotherapy with abiraterone		
		<u> </u>	The treatment remains appropriate and the patient is benefiting from treatment		

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRES	CRIBER		PATIENT:			
Name	:		Name:			
Ward:			NHI:			
Abiraterone acetate - continued						
CONTINUATION – pandemic circumstances Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)						
	O	The patient is clinically benefiting from treatment and continue	d treatment remains appropriate			
	and	Abiraterone acetate to be discontinued at progression				
		No initiation of taxane chemotherapy with abiraterone				
	and	The regular renewal requirements cannot be met due to COVI	D-19 constraints on the health sector			